KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Prepaid Assets (2017 - 2026)

Aquestive Therapeutics has reported Prepaid Assets over the past 9 years, most recently at $4.2 million for Q4 2025.

  • For Q4 2025, Prepaid Assets rose 26.84% year-over-year to $4.2 million; the TTM value through Dec 2025 reached $4.2 million, up 26.84%, while the annual FY2025 figure was $4.2 million, 26.84% up from the prior year.
  • Prepaid Assets for Q4 2025 was $4.2 million at Aquestive Therapeutics, up from $2.9 million in the prior quarter.
  • Over five years, Prepaid Assets peaked at $4.2 million in Q4 2025 and troughed at $1.2 million in Q2 2024.
  • A 5-year average of $2.4 million and a median of $2.1 million in 2022 define the central range for Prepaid Assets.
  • Biggest five-year swings in Prepaid Assets: tumbled 31.05% in 2023 and later skyrocketed 77.24% in 2024.
  • Year by year, Prepaid Assets stood at $3.1 million in 2021, then crashed by 30.74% to $2.1 million in 2022, then fell by 13.0% to $1.9 million in 2023, then skyrocketed by 77.24% to $3.3 million in 2024, then increased by 26.84% to $4.2 million in 2025.
  • Business Quant data shows Prepaid Assets for AQST at $4.2 million in Q4 2025, $2.9 million in Q3 2025, and $1.2 million in Q2 2025.